Olopatadine Exerts Multifaceted Protective Effects in an Ovalbumin-Induced Allergic Eye Disease Mouse Model
Bioengineering · 12.09.2026 · 13 (9) · 1060
DOI: 10.3390/bioengineering13091060 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioengineering, online erschienen am 12.09.2026. Verfasst von Basanta Bhujel und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Asan Medical Center, College of Medicine, University of Ulsan, Seoul 05505, Republic of Korea. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea (NRF), Asan Institute for Life Sciences.
Abstract (Originalsprache)
Allergic eye disease (AED), including allergic conjunctivitis, is a prevalent immune-mediated disorder of the ocular surface characterized by itching, redness, tearing, and ocular discomfort. Although olopatadine (OLO) is widely used as an antihistamine and mast cell stabilizer, its broader effects on immune-mediated inflammation, neuropeptide-associated responses, and epithelial–mucosal changes in AED remain incompletely understood. This study investigated the multifaceted effects of OLO in an ovalbumin (OVA)-induced AED mouse model. AED was induced in BALB/c mice by OVA sensitization and topical challenge, followed by OLO treatment during the challenge period. Clinical severity, scratching behavior, serum IgE, inflammatory cell infiltration (PMNs), mast cell degranulation, cytokine expression (IL-4, IL-5, IL-6, TNF-α, and IL-1β), macrophage infiltration (F4/80), iNOS expression, TRPV1, SP, and CGRP expression, ZO-1 expression, goblet cell density, mucin expression (MUC5AC), dysregulated cell proliferation (Ki67), and apoptotic cell death (TUNEL) were assessed. OVA challenge induced marked allergic responses, including elevated clinical scores, increased scratching behavior, elevated serum IgE, mast cell degranulation, inflammatory cell infiltration, and upregulation of Th2- and pro-inflammatory cytokines. In addition, OLO reduced TRPV1, SP, and CGRP expression, preserved ZO-1 expression and goblet cell density, and reduced excessive epithelial cell proliferation. Notably, OLO demonstrated multifaceted protective effects in AED, providing preclinical insights into its effects in experimental AED while acknowledging its established clinical use in humans.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Ophthalmology, Asan Medical Center, College of Medicine, University of Ulsan, Seoul 05505, Republic of Korea.
- Department of Medical Science, University of Ulsan Graduate School, Seoul 05505, Republic of Korea.
ORCID-Profile: Basanta Bhujel, Kyu Sang Eah, Jae-Yong Kim
Förderung
- National Research Foundation of Korea (NRF)
- Asan Institute for Life Sciences
Zitieren
APA
Bhujel, B., Eah, K. S., Kang, S. S., Chung, H. S., Lee, H., & Kim, J. Y. (2026). Olopatadine Exerts Multifaceted Protective Effects in an Ovalbumin-Induced Allergic Eye Disease Mouse Model. Bioengineering, 13(9), 1060. https://doi.org/10.3390/bioengineering13091060
Vancouver
Bhujel B, Eah KS, Kang SS, Chung HS, Lee H, Kim JY. Olopatadine Exerts Multifaceted Protective Effects in an Ovalbumin-Induced Allergic Eye Disease Mouse Model. Bioengineering. 2026;13(9):1060. doi:10.3390/bioengineering13091060
BibTeX
@article{Bhujel2026,
author = {Bhujel, Basanta and Eah, Kyu Sang and Kang, Soon Suk and Chung, Ho Seok and Lee, Hun and Kim, Jae-Yong},
title = {Olopatadine Exerts Multifaceted Protective Effects in an Ovalbumin-Induced Allergic Eye Disease Mouse Model},
journal = {Bioengineering},
year = {2026},
volume = {13},
number = {9},
pages = {1060},
doi = {10.3390/bioengineering13091060}
}
EUVIMED